Do a single nicotine pouch affect cigarette craving and brain response to smoking cues
Official title: Cue-Exposure Response Evaluation: Brain Reactivity to ONPs
Run by University of Southern California · NCT07698470 · Data updated 2026-11-12
This study tests whether a single 6 mg oral nicotine pouch can reduce craving and alter prefrontal brain responses to smoking cues in adults who smoke cigarettes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 55 Years |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | University of Southern California Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | April 30, 2026 |
| Main results expected | July 2027 |
| Study ends | August 2027 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT07698470 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 21-55 who smoke cigarettes daily or on most days, have a CO breath sample ≥10 ppm, and FTND score ≥5, and are willing to try an oral nicotine pouch while abstaining from nicotine before visits.
✕Probably not a fit
Individuals with very low nicotine dependence, non-smokers, or those unable to abstain from nicotine before visits may not experience a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm, within-subject study that examines the acute effects of an oral nicotine pouch on cigarette craving and prefrontal neural activity in response to smoking cues. After overnight nicotine abstinence, participants complete baseline craving assessments and a brain-imaging task using fNIRS while viewing smoking-related cues, then receive a 6 mg oral nicotine pouch and repeat the task. The study uses a baseline and experimental visit design with strict abstinence verification and a standardized cue-reactivity protocol. Enrollment targets adults aged 21-55 who smoke regularly and meet moderate-to-high nicotine dependence criteria. Primary outcomes focus on changes in self-reported craving and neural cue reactivity following pouch use.
Why it matters
Potential benefit: If successful, ONPs could offer a lower-risk option to reduce cigarette craving and cue-induced brain responses, aiding smoking reduction efforts.
How similar studies have gone: Prior research in nicotine replacement and cue-reactivity supports the potential for pharmacologic aids to modulate craving and neural responses, though this specific ONP and fNIRS approach is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 21 years - 55 years * Self-reported use of cigarettes within the past 30 days * Biochemical confirmation of cigarette use: o Carbon monoxide (CO) breath sample ≥10 ppm * Fagerström Test for Nicotine Dependence (FTND) score ≥5, indicating moderate to high nicotine dependence * Fluent in English * Willing to try an oral nicotine pouch * Willing to abstain from nicotine for at least 12 hours prior to each experimental session Exclusion Criteria: * Age younger than 21 years or older than 55 years * Biochemical evidence inconsistent with recent cigarette use: o CO breath sample \<10 ppm * Expressed intent to reduce or quit nicotine use within the next 30 days * History of medical conditions contraindicated for nicotine use (e.g., uncontrolled hypertension, recent cardiac events) * Primary use of non-cigarette products (e.g., cigars, pipe tobacco, smokeless tobacco) * Prior use of oral nicotine products in their lifetime
Where it's running
-
University of Southern California - 3641 Watt Way (HNB B22)
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Natalia Peraza — University of Southern California
- Study coordinator: USC Nicotine and Tobacco Studies
- Email: USCONPStudy@gmail.com
- Phone: 213-821-0807
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How people puff IQOS Iluma i vs IQOS 2.4 and how flavors feel
This study tests how exclusive IQOS users puff the newer Iluma i versus the older 2.4, and whether preferred flavor affects puffing and sensory experience.
-
TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
Ear acupressure plus nicotine replacement to ease withdrawal in psychiatric inpatients
This study will test whether adding ear acupressure (ear seeds) to standard nicotine replacement therapy helps psychiatric inpatients who must stop smoking reduce withdrawal symptoms, cravings, and anxiety.
-
Sex differences in how menthol e-cigarettes appeal to people who smoke
This study tests whether men and women differ in how menthol e-cigarettes with or without nicotine appeal to smokers who have used e-cigarettes before.
-
Perioperative high-dose nicotine patch for pain sensitivity in male smokers undergoing thoracic surgery
We will try a high-dose nicotine patch around the time of surgery to see if it reduces pain sensitivity in adult male smokers having thoracoscopic lung surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.